Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management

Oncology Letters

Volumn 14, Issue 5, 2017, Pages 5671-5680

  Stucci, Stefania ^a   Palmirotta, Raffaele ^a   Passarelli, Anna ^a   Silvestris, Erica ^a   Argentiero, Antonella ^a   Lanotte, Laura ^a   Acquafredda, Silvana ^a   Todisco, Annalisa ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Cytotoxic T lymphocyte associated antigen 4; Immune related adverse events; Immunotherapy; Management; Programmed cell death protein 1; Programmed cell death protein ligand 1

Indexed keywords

ANTINEOPLASTIC AGENT; BUDESONIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; INFLIXIMAB; LOPERAMIDE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PROGRAMMED DEATH 1 RECEPTOR INHIBITOR; TACROLIMUS; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; BRONCHOSCOPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLITIS; DIARRHEA; DISEASE SEVERITY; DRUG INDUCED DISEASE; ENDOCRINE DISEASE; HORMONE SUBSTITUTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RELATED ADVERSE EVENT; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INCIDENCE; KIDNEY INJURY; LIVER TOXICITY; MACULOPAPULAR RASH; PNEUMONIA; REVIEW; TUMOR MICROENVIRONMENT;

EID: 85030172706     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.6919     Document Type: Review

References (69)

1. Yang Y: Cancer immunotherapy: Harnessing the immune system to battle cancer. J Clin Invest 125: 3335-3337, 2015
2. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HM, et al: Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol 35 (Suppl): S185-S198, 2015
3. Gajewski TF, Schreiber H and Fu YX: Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14: 1014-1022, 2013
4. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012
5. Callahan MK, Postow MA and Wolchok JD: CTLA-4 and PD-1 pathway blockade: Combinations in the clinic. Front Oncol 4: 385, 2015
6. Tucci M, Stucci S, Passarelli A, Giudice G, Dammacco F and Silvestris F: The immune escape in melanoma: Role of the impaired dendritic cell function. Expert Rev Clin Immunol 10: 1395-1404, 2014
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010
8. Swaika A, Hammond WA and Joseph RW: Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol 67: 4-17, 2015
9. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122-133, 2013
10. Tarhini A: Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: The underlying mechanisms and clinical management. Scientifica (Cairo) 2013: 857519, 2013
11. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, et al: Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer 54: 139-148, 2016
12. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23-34, 2015
13. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al: Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17: 1558-1568, 2016
14. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012
15. Devaud C, John LB, Westwood JA, Darcy PK and Kershaw MH: Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2: e25961, 2013
16. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32: 1020-1030, 2014
17. Weber JS, Dummer R, de Pril V, Lebbé C and Hodi FS; MDX010-20 Investigators: Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119: 1675-1682, 2013
18. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, et al: Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11: 155-164, 2010
19. Abdel-Rahman O, ElHalawani H and Fouad M: Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Immunotherapy 7: 1213-1227, 2015
20. Postow MA, Callahan MK and Wolchok JD: Immune checkpoint blockade in cancer therapy. J Clin Oncol 33: 1974-1982, 2015
21. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372: 2521-2532, 2015
22. Bertrand A, Kostine M, Barnetche T, Truchetet ME and Schaeverbeke T: Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis. BMC Med 13: 211, 2015
23. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, et al: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24: 2283-2289, 2006
24. Ibrahim RA, Berman DM, DePril V, Humphrey RW, Chen T, Messina M, Chin KM, Liu HY, Bielefield M and Hoos A: Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. J Clin Oncol 29, 2011
25. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et al: Anti-p rogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 384: 1109-1117, 2014
26. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, et al: Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60: 210-225, 2016
27. Faje A: Immunotherapy and hypophysitis: Clinical presentation, treatment and biologic insights. Pituitary 19: 82-92, 2016
28. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, et al: Cutaneous, gastrointestinal, hepatic, endocrine and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60: 190-209, 2016
29. Barjaktarevic IZ, Qadir N, Suri A, Santamauro JT and Stover D: Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest 143: 858-861, 2013
30. Abdel-Rahman O and Fouad M: Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Ther Adv Respir Dis 10: 183-193, 2016
31. Papavasileiou E, Prasad S, Freitag SK, Sobrin L and Lobo AM: Ipilimumab-induced ocular and orbital inflammation-A case series and review of the literature. Ocul Immunol Inflamm 24: 140-146, 2016
32. Bot I, Blank CU, Boogerd W and Brandsma D: Neurological immune-related adverse events of ipilimumab. Pract Neurol 13: 278-280, 2013
33. Cappelli LC, Shah AA and Bingham CO III: Immune-related adverse effects of cancer immunotherapy-implications for rheumatology. Rheum Dis Clin North Am 43: 65-78, 2017
34. Goldstein BL, Gedmintas L and Todd DJ: Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol 66: 768-769, 2014
35. Fadel F, El Karoui K and Knebelmann B: Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361: 211-212, 2009
36. Forde PM, Rock K, Wilson G and O'Byrne KJ: Ipilimumab-induced immune-related renal failure--a case report. Anticancer Res 32: 4607-4608, 2012
37. Gordon IO, Wade T, Chin K, Dickstein J and Gajewski TF: Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 58: 1351-1353, 2009
38. Guo Y and Wang AY: Novel immune check-point regulators in tolerance maintenance. Fron Immunol 6: 421, 2015
39. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, et al: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506-511, 2003
40. Jin P, Xiang B, Huang G and Zhou Z: The association of cytotoxic T-lymphocyte antigen-4 + 49A/G and CT60 polymorphisms with type 1 diabetes and latent autoimmune diabetes in Chinese adults. J Endocrinol Invest 38: 149-154, 2015
41. Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A and Schadendorf D: Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: Identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 37: 485-498, 2010
42. Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, Targan SR and Wang HL: Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 10: 11, 2010
43. Nancey S, Boschetti G, Cotte E, Ruel K, Almeras T, Chauvenet M, Stroeymeyt K, Moussata D, Kaiserlian D and Flourié B: Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: A mechanistic explanation for ipilimumab-induced severe enterocolitis? Inflamm Bowel Dis 18: E1598-E1600, 2012
44. Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, Steinbach G and McDonald GB: Refractory colitis following anti-CTLA4 antibody therapy: Analysis of mucosal FOXP3+ T cells. Dig Dis Sci 55: 1396-1405, 2010
45. Callahan MK, Yang A, Tandon S, Xu Y, Subudhi SK, Roman RA, Heine AI, Pogoriler E, Kuk D, Panageas K, et al: Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. J Clin Oncol 29, 2011
46. Kähler KC and Hauschild A: Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges 9: 277-286, 2011 (In English, German)
47. Lacouture ME, Wolchok JD, Yosipovitch G, Kähler KC, Busam KJ and Hauschild A: Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 71: 161-169, 2014
48. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, et al: A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15: 5591-5598, 2009
49. Weber JS, Kähler KC and Hauschild A: Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30: 2691-2697, 2012
50. Villadolid J and Amin A: Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities. Transl Lung Cancer Res 4: 560-575, 2015
51. Weber JS, Berman D, Siegel J, Minor D, Amin A, Thompson JA, Ron I, Ridolfi R, Assi H and Hamid O: Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. J Clin Oncol, 2008
52. Spain L, Diem S and Larkin J: Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44: 51-60, 2016
53. Friedman CF, Proverbs-Singh TA and Postow MA: Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncol 2: 1346-1353, 2016
54. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K and Ortiz-Urda S: Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151: 1206-1212, 2015
55. Lacouture ME: Management of dermatologic toxicities. J Natl Compr Canc Netw 13 (5 Suppl): S686-S689, 2015
56. Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA and Velcheti V: Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials. Chest 152: 271-281, 2017
57. Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS and Nishino M: Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3: 1185-1192, 2015
58. Nishino M, Chambers ES, Chong CR, Ramaiya NH, Gray SW, Marcoux JP, Hatabu H, Jänne PA, Hodi FS and Awad MM: Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol Res 4: 289-293, 2016
59. Dillard T, Yedinak CG, Alumkal J and Fleseriu M: Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 13: 29-38, 2010
60. Lammert A, Schneider HJ, Bergmann T, Benck U, Krämer BK, Gärtner R, Metzner C, Schöfl C and Berking C: Hypophysitis caused by ipilimumab in cancer patients: Hormone replacement or immunosuppressive therapy. Exp Clin Endocrinol Diabetes 121: 581-587, 2013
61. González-Rodríguez E and Rodríguez-Abreu D; Spanish Group for Cancer Immuno-Biotherapy (GETICA): Immune checkpoint inhibitors: Review and management of endocrine adverse events. Oncologist 21: 804-816, 2016
62. Orlov S, Salari F, Kashat L and Walfish PG: Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab 100: 1738-1741, 2015
63. Amin A, DePril V, Hamid O, Wolchock J, Maio M, Neyns B, Chin K, Ibrahim R, Hoos A and O'Day S: Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. J Clin Oncol 27, 2009
64. Suarez-Almazor ME, Kim ST, Abdel-Wahab N and Diab A: Review: Immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol 69: 687-699, 2017
65. Joshi S, Pantalena LC, Liu XK, Gaffen SL, Liu H, Rohowsky-Kochan C, Ichiyama K, Yoshimura A, Steinman L, Christakos S and Youssef S: 1,25-dihydroxyvitamin D (3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 31: 3653-3669, 2011
66. Deeb KK, Trump DL and Johnson CS: Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat Rev Cancer 7: 684-700, 2007
67. Roy S and Trinchieri G: Microbiota: A key orchestrator of cancer therapy. Nat Rev Cancer 17: 271-285, 2017
68. Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, et al: Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350: 1079-1084, 2015
69. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, et al: Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350: 1084-1089, 2015.